Why did EpiPen's price skyrocket 400 percent over the past decade? Sarah and Matt dive into the complex world of American drug pricing to find out. Also on this episode: understanding why the Clinton Foundation gets so much scrutiny, and a white paper of the week that shows how problematic a small level of lead exposure can be.
Learn more about your ad choices. Visit podcastchoices.com/adchoices
To view this and other transcripts, as well as support the generation of new transcripts, please subscribe.